Cepacia syndrome (CS) is a fatal septic condition that develops in approximately 20% of cystic fibrosis (CF) patients chronically infected with the Burkholderia cepacia complex (Bcc). The most common causative agent is Burkholderia cenocepacia, a clinically dominant Bcc species that contains the globally distributed epidemic strain sequence type 32 (ST32). Using microarrays, we compared the transcriptomes of ST32 isolates from the bloodstream at the time of CS with their sputum counterparts recovered 1 to 2 months prior to the development of CS. Global gene expression profiles of blood isolates revealed greater activities of the virulence genes involved in the type III secretion system, the bacterial exopolysaccharide cepacian, and quorum sensing, while reduced expression was demonstrated for flagellar genes. Furthermore, a nonmotile phenotype (as evaluated by a swimming motility assay) was identified in blood isolates from 6 out of 8 patients with CS; this phenotype was traceable to 24 months prior to the onset of CS. Loss of motility was not observed in any of the 89 ST32 isolates recovered over the course of chronic infection from 17 patients without CS. In conclusion, the gene expression of Bcc bacteria disseminated during CS has been elucidated for the first time. This study demonstrated marked differences at the transcriptome level between isogenic ST32 isolates that are attributable to the stage and site of infection. The finding of a nonmotile B. cenocepacia isolate may serve as a warning sign for the development of CS in the near future.

Department of Medical Microbiology 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

Department of Pneumology 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

Institute of Molecular Genetics Academy of Sciences Prague Czech Republic

Zobrazit více v PubMed

Peeters C, Zlosnik JE, Spilker T, Hird TJ, Lipuma JJ, Vandamme P. 2013. Burkholderia pseudomultivorans sp. nov., a novel Burkholderia cepacia complex species from human respiratory samples and the rhizosphere. Syst Appl Microbiol 36:483–489. doi:10.1016/j.syapm.2013.06.003. PubMed DOI

Chernish RN, Aaron SD. 2003. Approach to resistant Gram-negative bacterial pulmonary infections in patients with cystic fibrosis. Curr Opin Pulm Med 9:509–515. doi:10.1097/00063198-200311000-00011. PubMed DOI

Mahenthiralingam E, Urban TA, Goldberg JB. 2005. The multifarious, multireplicon Burkholderia cepacia complex. Nat Rev Microbiol 3:144–156. doi:10.1038/nrmicro1085. PubMed DOI

Govan JR, Brown PH, Maddison J, Doherty CJ, Nelson JW, Dodd M, Greening AP, Webb AK. 1993. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet 342:15–19. doi:10.1016/0140-6736(93)91881-L. PubMed DOI

Drevinek P, Vosahlikova S, Cinek O, Vavrova V, Bartosova J, Pohunek P, Mahenthiralingam E. 2005. Widespread clone of Burkholderia cenocepacia in cystic fibrosis patients in the Czech Republic. J Med Microbiol 54:655–659. doi:10.1099/jmm.0.46025-0. PubMed DOI

Kalish LA, Waltz DA, Dovey M, Potter-Bynoe G, McAdam AJ, Lipuma JJ, Gerard C, Goldmann D. 2006. Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis. Am J Respir Crit Care Med 173:421–425. doi:10.1164/rccm.200503-344OC. PubMed DOI

Blackburn L, Brownlee K, Conway S, Denton M. 2004. “Cepacia syndrome” with Burkholderia multivorans, 9 years after initial colonization. J Cyst Fibros 3:133–134. doi:10.1016/j.jcf.2004.03.007. PubMed DOI

Drevinek P, Mahenthiralingam E. 2010. Burkholderia cenocepacia in cystic fibrosis: epidemiology and molecular mechanisms of virulence. Clin Microbiol Infect 16:821–830. doi:10.1111/j.1469-0691.2010.03237.x. PubMed DOI

Dedeckova K, Kalferstova L, Strnad H, Vavrova J, Drevinek P. 2013. Novel diagnostic PCR assay for Burkholderia cenocepacia epidemic strain ST32 and its utility in monitoring infection in cystic fibrosis patients. J Cyst Fibros 12:475–481. doi:10.1016/j.jcf.2012.12.007. PubMed DOI

Holden MT, Seth-Smith HM, Crossman LC, Sebaihia M, Bentley SD, Cerdeno-Tarraga AM, Thomson NR, Bason N, Quail MA, Sharp S, Cherevach I, Churcher C, Goodhead I, Hauser H, Holroyd N, Mungall K, Scott P, Walker D, White B, Rose H, Iversen P, Mil-Homens D, Rocha EP, Fialho AM, Baldwin A, Dowson C, Barrell BG, Govan JR, Vandamme P, Hart CA, Mahenthiralingam E, Parkhill J. 2009. The genome of Burkholderia cenocepacia J2315, an epidemic pathogen of cystic fibrosis patients. J Bacteriol 191:261–277. doi:10.1128/JB.01230-08. PubMed DOI PMC

LiPuma JJ, Spilker T, Coenye T, Gonzalez CF. 2002. An epidemic Burkholderia cepacia complex strain identified in soil. Lancet 359:2002–2003. doi:10.1016/S0140-6736(02)08836-0. PubMed DOI

Dobbin K, Shih JH, Simon R. 2003. Statistical design of reverse dye microarrays. Bioinformatics 19:803–810. doi:10.1093/bioinformatics/btg076. PubMed DOI

Drevinek P, Holden MT, Ge Z, Jones AM, Ketchell I, Gill RT, Mahenthiralingam E. 2008. Gene expression changes linked to antimicrobial resistance, oxidative stress, iron depletion and retained motility are observed when Burkholderia cenocepacia grows in cystic fibrosis sputum. BMC Infect Dis 8:121. doi:10.1186/1471-2334-8-121. PubMed DOI PMC

Smyth G. 2005. Limma: linear models for microarray data, p 397–420. In Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W (ed), Bioinformatics and computational biology solutions using R and Bioconductor. Springer, New York, NY.

Sass A, Drevinek P, Sokol PA. 2014. Comparative transcriptomics in Burkholderia, p 77–98. In Coenye T, Mahenthiralingam E (ed), Burkholderia: from genomes to function. Caister Academic Press, Norfolk, United Kingdom.

Agnoli K, Schwager S, Uehlinger S, Vergunst A, Viteri DF, Nguyen DT, Sokol PA, Carlier A, Eberl L. 2012. Exposing the third chromosome of Burkholderia cepacia complex strains as a virulence plasmid. Mol Microbiol 83:362–378. doi:10.1111/j.1365-2958.2011.07937.x. PubMed DOI

Mira NP, Madeira A, Moreira AS, Coutinho CP, Sa-Correia I. 2011. Genomic expression analysis reveals strategies of Burkholderia cenocepacia to adapt to cystic fibrosis patients' airways and antimicrobial therapy. PLoS One 6:e28831. doi:10.1371/journal.pone.0028831. PubMed DOI PMC

O'Grady EP, Sokol PA. 2011. Burkholderia cenocepacia differential gene expression during host-pathogen interactions and adaptation to the host environment. Front Cell Infect Microbiol 1:15. doi:10.3389/fcimb.2011.00015. PubMed DOI PMC

Loutet SA, Di Lorenzo F, Clarke C, Molinaro A, Valvano MA. 2011. Transcriptional responses of Burkholderia cenocepacia to polymyxin B in isogenic strains with diverse polymyxin B resistance phenotypes. BMC Genomics 12:472. doi:10.1186/1471-2164-12-472. PubMed DOI PMC

Sass A, Marchbank A, Tullis E, Lipuma JJ, Mahenthiralingam E. 2011. Spontaneous and evolutionary changes in the antibiotic resistance of Burkholderia cenocepacia observed by global gene expression analysis. BMC Genomics 12:373. doi:10.1186/1471-2164-12-373. PubMed DOI PMC

Diaz MR, King JM, Yahr TL. 2011. Intrinsic and extrinsic regulation of type III secretion gene expression in Pseudomonas aeruginosa. Front Microbiol 2:89. doi:10.3389/fmicb.2011.00089. PubMed DOI PMC

Amiel E, Lovewell RR, O'Toole GA, Hogan DA, Berwin B. 2010. Pseudomonas aeruginosa evasion of phagocytosis is mediated by loss of swimming motility and is independent of flagellum expression. Infect Immun 78:2937–2945. doi:10.1128/IAI.00144-10. PubMed DOI PMC

Conway BA, Chu KK, Bylund J, Altman E, Speert DP. 2004. Production of exopolysaccharide by Burkholderia cenocepacia results in altered cell-surface interactions and altered bacterial clearance in mice. J Infect Dis 190:957–966. doi:10.1086/423141. PubMed DOI

Zlosnik JE, Mori PY, To D, Leung J, Hird TJ, Speert DP. 2014. Swimming motility in a longitudinal collection of clinical isolates of Burkholderia cepacia complex bacteria from people with cystic fibrosis. PLoS One 9:e106428. doi:10.1371/journal.pone.0106428. PubMed DOI PMC

Omics Analysis of Blood-Responsive Regulon in Bordetella pertussis Identifies a Novel Essential T3SS Substrate

What matters in chronic Burkholderia cenocepacia infection in cystic fibrosis: Insights from comparative genomics

Understanding the Pathogenicity of Burkholderia contaminans, an Emerging Pathogen in Cystic Fibrosis